Proposed Data Collections Submitted for Public Comment and Recommendations, 71796-71797 [2012-29176]
Download as PDF
<![CDATA[
71796
Federal Register / Vol. 77, No. 233 / Tuesday, December 4, 2012 / Notices
There will be no cost to the
respondents other than their time. The
total burden is 216.
ESTIMATED ANNUALIZED BURDEN HOURS
Respondents
Phase I ..................................
Form name
Section Foreman ..................
Phase I Section Foreman
Form.
Phase I Baseline Form .........
Phase I 1month form ............
Phase I Focus Group Questions.
Phase II Section Foreman
Form.
Phase II Baseline Form ........
Phase II 1, 3, and 6 months
forms.
Mine Workers .......................
Mine Workers .......................
Mine Workers .......................
Phase II .................................
Section Foreman ..................
Mine Workers .......................
Mine Workers .......................
Dated: November 26, 2012.
Ron A. Otten,
Director, Office of Scientific Integrity (OSI),
Office of the Associate Director for Science
(OADS), Office of the Director, Centers for
Disease Control and Prevention.
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
[FR Doc. 2012–29182 Filed 12–3–12; 8:45 am]
BILLING CODE 4163–18–P
Proposed Project
Laboratory Medicine Best Practices
Project (LMBP), OMB Control Number
0920–0848, Expiration 5/31/2013—
EXTENSION—Office of Surveillance,
Epidemiology and Laboratory Services
(OSELS), Centers for Disease Control
and Prevention (CDC).
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60 Day-13–0848]
mstockstill on DSK4VPTVN1PROD with
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–7570 and
send comments to Ron Otten, 1600
Clifton Road, MS–D74, Atlanta, GA
30333 or send an email to omb@cdc.gov.
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
VerDate Mar<15>2010
17:31 Dec 03, 2012
Jkt 229001
Background and Brief Description
CDC is seeking approval from the
Office of Management and Budget
(OMB) to collect information from
healthcare organizations in order to
conduct systemic evidence reviews of
laboratory practice effectiveness. The
purpose of information collection is to
include completed unpublished quality
improvement studies/assessments
carried out by healthcare organizations
(laboratories, hospitals, clinics) in
systematic reviews of practice
effectiveness. CDC has been sponsoring
the Laboratory Medicine Best Practices
initiative to develop new systematic
evidence reviews methods for making
evidence-based recommendations in
laboratory medicine. This initiative
supports the CDC’s mission of
improving laboratory practices. The
focus of the Initiative is on pre- and
post-analytic laboratory medicine
practices that are effective at improving
health care quality. While evidence
based approaches for decision-making
have become standard in healthcare,
this has been limited in laboratory
medicine. No single-evidence-based
PO 00000
Frm 00025
Fmt 4703
Sfmt 4703
No. of
responses per
respondent
No. of
respondents
Average
burden per
response
(in hours)
3
1
30/60
27
27
27
1
1
1
20/60
30/60
1
6
12
10/60
54
54
1
6
20/60
25/60
model for recommending practices in
laboratory medicine exists, although the
number of laboratories operating in the
United States and the volume of
laboratory tests available certainly
warrant such a model. The Laboratory
Medicine Best Practices Initiative began
in October 2006, when CDC convened
the Laboratory Medicine Best Practices
Workgroup (Workgroup), a
multidisciplinary panel of experts in
several fields including laboratory
medicine, clinical medicine, health
services research, and health care
performance measurement. The
Workgroup has been supported by staff
at CDC and the Battelle Memorial
Institute under contract to CDC. To date,
the Laboratory Medicine Best Practices
(LMBP) project work has been
completed over three phases. During
Phase 1 (October 2006–September
2007)of the project, CDC staff developed
systematic review methods for
conducting evidence reviews using
published literature, and completed a
proof-of-concept test. Results of an
extensive search and review of
published literature using the methods
for the topic of patient specimen
identification indicated that an
insufficient quality and number of
studies were available for completing
systematic evidence reviews of
laboratory medicine practice
effectiveness for multiple practices, and
hence for making evidence-based
recommendations. These results were
considered likely to be generalizable to
most potential topic areas of interest. A
finding from Phase 1 work was that
laboratories would be unlikely to
publish quality improvement projects or
studies demonstrating practice
effectiveness in the peer reviewed
literature, but that they routinely
E:\FR\FM\04DEN1.SGM
04DEN1
71797
Federal Register / Vol. 77, No. 233 / Tuesday, December 4, 2012 / Notices
conducted quality improvement projects
and had relevant data for completion of
evidence reviews. Phase 2 (September
2007–November 2008) and Phase 3
(December 2008–September 2009),
involved further methods development
and pilot tests to obtain, review, and
evaluate published and unpublished
evidence for practices associated with
the topics of patient specimen
identification, communicating critical
value test results, and blood culture
contamination. Exploratory work by
LMBP registrant network and submit
readily available unpublished studies;
quality improvement projects,
evaluations, assessments, and other
analyses relying on unlinked,
anonymous data using the LMBP
Submission Form. LMBP registrants will
also be able to submit unpublished
studies/data for evidence reviews on an
annual basis using this form. There is no
cost to respondents other than their
time.
CDC supports the existence of relevant
unpublished studies or completed
quality improvement projects related to
laboratory medicine practices from
healthcare organizations. The objective
for successive LMBP evidence reviews
of practice effectiveness is to
supplement the published evidence
with unpublished evidence to fill in
gaps in the literature. Healthcare
organizations and facilities (laboratory,
hospital, clinic) will have the
opportunity to voluntarily enroll in an
ESTIMATED ANNUALIZED BURDEN HOURS
No. of
responses per
respondent
No. of
respondents
Respondents
Average
burden per
response
(in hrs)
Total burden
(in hours) *
Healthcare Organizations ................................................................................
150
1
40/60
100
Total ..........................................................................................................
........................
........................
........................
100
Dated: November 26, 2012.
Ron A. Otten,
Director, Office of Scientific Integrity (OSI),
Office of the Associate Director for Science
(OADS), Office of the Director, Centers for
Disease Control and Prevention.
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of information technology. Written
comments should be received within 60
days of this notice.
[FR Doc. 2012–29176 Filed 12–3–12; 8:45 am]
BILLING CODE 4163–18–P
Proposed Project
School Dismissal Monitoring System
(OMB Control No. 0920–0849 Exp. 5/31/
2013)—Revision—National Center
Emerging and Zoonotic Infectious
Diseases (NCEZID), Centers for Disease
Control and Prevention (CDC).
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60 Day-13–0849]
mstockstill on DSK4VPTVN1PROD with
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–7570 and
send comments to Ron Otten, 1600
Clifton Road, MS–D74, Atlanta, GA
30333 or send an email to omb@cdc.gov.
Comments are invited on (a) whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have a
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
VerDate Mar<15>2010
17:31 Dec 03, 2012
Jkt 229001
Background and Brief Description
In the spring of 2009, the beginning of
H1N1 influenza pandemic, illness
among school-aged students (K–12) in
many states and cities resulted in at
least 1,351 school dismissals due to
rapidly increasing absenteeism among
students or staff. These dismissals
impacted at least 824,966 students and
53,217 teachers. During that time, the
U.S. Department of Education (ED) and
the Centers for Disease Control and
Prevention (CDC) received numerous
daily requests about the overall number
of school dismissals nationwide and the
number of students and teachers
impacted by the school dismissals. CDC
and ED recognized the importance of
having a mechanism in place to collect
this information and gauge the impact of
school dismissals during the pandemic.
Although an informal process was put
in place in conjunction with ED to track
school closures, there was no formal
monitoring system established.
Consequently, CDC and ED launched
the School Dismissal Monitoring System
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
to track reports of school closures
during public health emergencies and
generate accurate, real-time, national
summary data daily on the number of
closed schools and the number of
students and teachers impacted by the
dismissals. The system, initially
approved under OMB Control No. 0920–
0008, Emergency Epidemic
Investigations, facilitated CDC’s and
ED’s efforts to track implementation of
CDC pandemic guidance, characterized
factors associated with differences in
morbidity and mortality due to
pandemic influenza in the schools and
surrounding communities, and
described the characteristics of the
schools experiencing outbreaks as well
as control measures undertaken by those
schools. In the fall of 2009, CDC’s
School Dismissal Monitoring System
detected 1,947 school dismissals
impacting approximately 623,616
students and 40,521 teachers
nationwide. These data were used
widely throughout the U.S. Government
for situational awareness and
specifically at CDC to assess the impact
of CDC guidance and community
mitigation efforts in response to the
2009 H1N1 influenza pandemic.
The purpose of this monitoring
system is to generate accurate, real-time,
national summary data daily on the
number of school dismissals and the
number of students and teachers
impacted by the dismissals due to
public health emergencies. This
collection request includes dismissals
initiated for infectious disease outbreaks
or weather related events when school
dismissals are recommended by federal,
state or local public health authorities.
E:\FR\FM\04DEN1.SGM
04DEN1
]]>Agencies
[Federal Register Volume 77, Number 233 (Tuesday, December 4, 2012)]
[Notices]
[Pages 71796-71797]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-29176]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[60 Day-13-0848]
Proposed Data Collections Submitted for Public Comment and
Recommendations
In compliance with the requirement of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for opportunity for public comment on
proposed data collection projects, the Centers for Disease Control and
Prevention (CDC) will publish periodic summaries of proposed projects.
To request more information on the proposed projects or to obtain a
copy of the data collection plans and instruments, call 404-639-7570
and send comments to Ron Otten, 1600 Clifton Road, MS-D74, Atlanta, GA
30333 or send an email to omb@cdc.gov.
Comments are invited on: (a) Whether the proposed collection of
information is necessary for the proper performance of the functions of
the agency, including whether the information shall have practical
utility; (b) the accuracy of the agency's estimate of the burden of the
proposed collection of information; (c) ways to enhance the quality,
utility, and clarity of the information to be collected; and (d) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques or other
forms of information technology. Written comments should be received
within 60 days of this notice.
Proposed Project
Laboratory Medicine Best Practices Project (LMBP), OMB Control
Number 0920-0848, Expiration 5/31/2013--EXTENSION--Office of
Surveillance, Epidemiology and Laboratory Services (OSELS), Centers for
Disease Control and Prevention (CDC).
Background and Brief Description
CDC is seeking approval from the Office of Management and Budget
(OMB) to collect information from healthcare organizations in order to
conduct systemic evidence reviews of laboratory practice effectiveness.
The purpose of information collection is to include completed
unpublished quality improvement studies/assessments carried out by
healthcare organizations (laboratories, hospitals, clinics) in
systematic reviews of practice effectiveness. CDC has been sponsoring
the Laboratory Medicine Best Practices initiative to develop new
systematic evidence reviews methods for making evidence-based
recommendations in laboratory medicine. This initiative supports the
CDC's mission of improving laboratory practices. The focus of the
Initiative is on pre- and post-analytic laboratory medicine practices
that are effective at improving health care quality. While evidence
based approaches for decision-making have become standard in
healthcare, this has been limited in laboratory medicine. No single-
evidence-based model for recommending practices in laboratory medicine
exists, although the number of laboratories operating in the United
States and the volume of laboratory tests available certainly warrant
such a model. The Laboratory Medicine Best Practices Initiative began
in October 2006, when CDC convened the Laboratory Medicine Best
Practices Workgroup (Workgroup), a multidisciplinary panel of experts
in several fields including laboratory medicine, clinical medicine,
health services research, and health care performance measurement. The
Workgroup has been supported by staff at CDC and the Battelle Memorial
Institute under contract to CDC. To date, the Laboratory Medicine Best
Practices (LMBP) project work has been completed over three phases.
During Phase 1 (October 2006-September 2007)of the project, CDC staff
developed systematic review methods for conducting evidence reviews
using published literature, and completed a proof-of-concept test.
Results of an extensive search and review of published literature using
the methods for the topic of patient specimen identification indicated
that an insufficient quality and number of studies were available for
completing systematic evidence reviews of laboratory medicine practice
effectiveness for multiple practices, and hence for making evidence-
based recommendations. These results were considered likely to be
generalizable to most potential topic areas of interest. A finding from
Phase 1 work was that laboratories would be unlikely to publish quality
improvement projects or studies demonstrating practice effectiveness in
the peer reviewed literature, but that they routinely
[[Page 71797]]
conducted quality improvement projects and had relevant data for
completion of evidence reviews. Phase 2 (September 2007-November 2008)
and Phase 3 (December 2008-September 2009), involved further methods
development and pilot tests to obtain, review, and evaluate published
and unpublished evidence for practices associated with the topics of
patient specimen identification, communicating critical value test
results, and blood culture contamination. Exploratory work by CDC
supports the existence of relevant unpublished studies or completed
quality improvement projects related to laboratory medicine practices
from healthcare organizations. The objective for successive LMBP
evidence reviews of practice effectiveness is to supplement the
published evidence with unpublished evidence to fill in gaps in the
literature. Healthcare organizations and facilities (laboratory,
hospital, clinic) will have the opportunity to voluntarily enroll in an
LMBP registrant network and submit readily available unpublished
studies; quality improvement projects, evaluations, assessments, and
other analyses relying on unlinked, anonymous data using the LMBP
Submission Form. LMBP registrants will also be able to submit
unpublished studies/data for evidence reviews on an annual basis using
this form. There is no cost to respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
No. of No. of burden per Total burden
Respondents respondents responses per response (in (in hours) *
respondent hrs)
----------------------------------------------------------------------------------------------------------------
Healthcare Organizations........................ 150 1 40/60 100
---------------------------------------------------------------
Total....................................... .............. .............. .............. 100
----------------------------------------------------------------------------------------------------------------
Dated: November 26, 2012.
Ron A. Otten,
Director, Office of Scientific Integrity (OSI), Office of the Associate
Director for Science (OADS), Office of the Director, Centers for
Disease Control and Prevention.
[FR Doc. 2012-29176 Filed 12-3-12; 8:45 am]
BILLING CODE 4163-18-P
